A Multi-Center, Prospective, Observational Study to Evaluate the Therapeutic Effectiveness and Safety of an Olmesartan/Amlodipine Plus Rosuvastatin Combination Treatment in Patients with Concomitant Hypertension and Dyslipidemia

  • Bong Ki Lee
  • , Byeong Keuk Kim
  • , Jae Hyoung Park
  • , Jong Won Chung
  • , Chang Gyu Park
  • , Jin Won Kim
  • , Young Dae Kim
  • , Woo Jung Park
  • , Sang Hyun Kim
  • , Jae Kwan Cha
  • , Cheol Ho Kim
  • , Seung Woon Rha
  • , Young Joon Hong
  • , Mi Seung Shin
  • , Seong Wook Cho
  • , Young Hee Sung
  • , Kiheon Lee
  • , Jae Myung Yu
  • , Dong Ryeol Ryu
  • , Sungwook Yu
  • Tae Jin Song, Bon D. Ku, Sin Gon Kim, Hwan Cheol Park, Deok Kyu Cho, Byung Su Kim, Seong Woo Han, Sung Ji Park, Gyung Min Park, Kyoo Rok Han*
*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: This study assessed the therapeutic effectiveness of a single-pill combination (SPC) of olmesartan/amlodipine plus rosuvastatin for blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C) in patients with hypertension and dyslipidemia. Methods: Adult patients with hypertension and dyslipidemia who were decided to be treated with the study drug were eligible. The primary endpoint was the proportion of patients who achieved BP, LDL-C and both BP and LDL-C treatment goals at weeks 24–48. Secondary endpoints were assessed at weeks 24–48 and included changes in BP and LDL-C levels from baseline; the proportion of patients who achieved treatment goals who were initially classified as uncontrolled at baseline; changes and percent changes in lipid parameters; changes in both BP and LDL-C levels among patients who reached treatment goals who were followed for more than 24 weeks; and the overall safety profile. Results: A total of 5476 patients were enrolled, and 4411 patients comprised the effectiveness evaluation set. The proportions of patients who reached the treatment goals for BP, LDL-C levels, and both BP and LDL-C levels were 67.93% [95% confidence interval (CI) 66.52–69.32], 80.19% [95% CI 78.85–81.49], and 58.07% [95% CI 56.43–59.7], respectively. Secondary endpoints showed statistically significant changes. Overall, the treatment was well tolerated. Conclusions: The treatment of patients with hypertension and dyslipidemia with the olmesartan/amlodipine plus rosuvastatin SPC was associated with significant decreases in SBP/DBP and LDL-C levels, and a high proportion of patients achieved the BP and LDL-C treatment goals. The finding of this study is worthwhile in that this study evaluated the effectiveness and safety in a broad patient population representative of those seen in everyday clinical practice.

Original languageEnglish
Article number308
JournalJournal of Clinical Medicine
Volume14
Issue number2
DOIs
Publication statusPublished - 2025 Jan

Bibliographical note

Publisher Copyright:
© 2025 by the authors.

Keywords

  • blood pressure
  • dyslipidemia
  • hypertension
  • low-density lipoprotein cholesterol
  • observational study
  • single-pill combination

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'A Multi-Center, Prospective, Observational Study to Evaluate the Therapeutic Effectiveness and Safety of an Olmesartan/Amlodipine Plus Rosuvastatin Combination Treatment in Patients with Concomitant Hypertension and Dyslipidemia'. Together they form a unique fingerprint.

Cite this